27 results on '"Pries‐Heje, Mia"'
Search Results
2. Association Between Vegetation Size and Outcome in the Partial Oral Antibiotic Endocarditis Treatment Trial
- Author
-
Carter-Storch, Rasmus, Pries-Heje, Mia Marie, Povlsen, Jonas A., Christensen, Ulrik, Gill, Sabine U., Hjulmand, Julie Glud, Bruun, Niels E., Elming, Hanne, Madsen, Trine, Fuursted, Kurt, Schultz, Martin, Christensen, Jens J., Rosenvinge, Flemming, Helweg-Larsen, Jannik, Fosbøl, Emil, Køber, Lars, Torp-Pedersen, Christian, Tønder, Niels, Moser, Claus, Iversen, Kasper, Bundgaard, Henning, and Ihlemann, Nikolaj
- Published
- 2024
- Full Text
- View/download PDF
3. Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
- Author
-
Pérez-Alós, Laura, Hansen, Cecilie Bo, Almagro Armenteros, Jose Juan, Madsen, Johannes Roth, Heftdal, Line Dam, Hasselbalch, Rasmus Bo, Pries-Heje, Mia Marie, Bayarri-Olmos, Rafael, Jarlhelt, Ida, Hamm, Sebastian Rask, Møller, Dina Leth, Sørensen, Erik, Ostrowski, Sisse Rye, Frikke-Schmidt, Ruth, Hilsted, Linda Maria, Bundgaard, Henning, Nielsen, Susanne Dam, Iversen, Kasper Karmark, and Garred, Peter
- Published
- 2023
- Full Text
- View/download PDF
4. Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study
- Author
-
Heftdal, Line Dam, Pérez-Alós, Laura, Hasselbalch, Rasmus Bo, Hansen, Cecilie Bo, Hamm, Sebastian Rask, Møller, Dina Leth, Pries-Heje, Mia, Fogh, Kamille, Gerstoft, Jan, Grønbæk, Kirsten, Ostrowski, Sisse Rye, Frikke-Schmidt, Ruth, Sørensen, Erik, Hilsted, Linda, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, Sabin, Caroline, and Nielsen, Susanne Dam
- Published
- 2023
- Full Text
- View/download PDF
5. Self-assessed health status and associated mortality in endocarditis: secondary findings from the POET trial
- Author
-
Bundgaard, Johan S., Iversen, Kasper, Pries-Heje, Mia, Ihlemann, Nikolaj, Gill, Sabine U., Madsen, Trine, Elming, Hanne, Povlsen, Jonas A., Bruun, Niels E., Høfsten, Dan E., Fuursted, Kurt, Christensen, Jens J., Schultz, Martin, Rosenvinge, Flemming, Helweg‑Larsen, Jannik, Køber, Lars, Torp‑Pedersen, Christian, Fosbøl, Emil L., Tønder, Niels, Moser, Claus, Bundgaard, Henning, and Mogensen, Ulrik M.
- Published
- 2022
- Full Text
- View/download PDF
6. Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers
- Author
-
Iversen, Kasper, Kristensen, Jonas Henrik, Hasselbalch, Rasmus Bo, Pries-Heje, Mia, Nielsen, Pernille Brok, Knudsen, Andreas Dehlbæk, Fogh, Kamille, Norsk, Jakob Boesgaard, Andersen, Ove, Fischer, Thea Køhler, Juul Jensen, Claus Antonio, Torp-Pedersen, Christian, Rungby, Jørgen, Ditlev, Sisse Bolm, Hageman, Ida, Møgelvang, Rasmus, Gybel-Brask, Mikkel, Dessau, Ram B., Sørensen, Erik, Harritshøj, Lene, Folke, Fredrik, Sten, Curt, Engel Møller, Maria Elizabeth, Benfield, Thomas, Ullum, Henrik, Jørgensen, Charlotte Sværke, Erikstrup, Christian, Ostrowski, Sisse R., Nielsen, Susanne Dam, and Bundgaard, Henning
- Published
- 2022
- Full Text
- View/download PDF
7. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors
- Author
-
Pérez-Alós, Laura, Armenteros, Jose Juan Almagro, Madsen, Johannes Roth, Hansen, Cecilie Bo, Jarlhelt, Ida, Hamm, Sebastian Rask, Heftdal, Line Dam, Pries-Heje, Mia Marie, Møller, Dina Leth, Fogh, Kamille, Hasselbalch, Rasmus Bo, Rosbjerg, Anne, Brunak, Søren, Sørensen, Erik, Larsen, Margit Anita Hørup, Ostrowski, Sisse Rye, Frikke-Schmidt, Ruth, Bayarri-Olmos, Rafael, Hilsted, Linda Maria, Iversen, Kasper Karmark, Bundgaard, Henning, Nielsen, Susanne Dam, and Garred, Peter
- Published
- 2022
- Full Text
- View/download PDF
8. The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial
- Author
-
Bundgaard, Johan S., Iversen, Kasper, Pries-Heje, Mia, Ihlemann, Nikolaj, Bak, Theis S., Østergaard, Lauge, Gill, Sabine U., Madsen, Trine, Elming, Hanne, Jensen, Kaare T., Bruun, Niels E., Høfsten, Dan E., Fuursted, Kurt, Christensen, Jens J., Schultz, Martin, Rosenvinge, Flemming, Schønheyder, Henrik C., Helweg-Larsen, Jannik, Køber, Lars, Torp-Pedersen, Christian, Fosbøl, Emil L., Tønder, Niels, Moser, Claus, Bundgaard, Henning, and Mogensen, Ulrik M.
- Published
- 2022
- Full Text
- View/download PDF
9. Implications of Age for the Diagnostic and Prognostic Value of Cardiac Troponin T and I.
- Author
-
Hasselbalch, Rasmus Bo, Schytz, Philip Andreas, Schultz, Martin, Sindet-Pedersen, Caroline, Kristensen, Jonas Henrik, Strandkjær, Nina, Knudsen, Sophie Sander, Pries-Heje, Mia, Pareek, Manan, Kragholm, Kristian H, Carlson, Nicholas, Schou, Morten, Andersen, Mikkel Porsborg, Bundgaard, Henning, Torp-Pedersen, Christian, and Iversen, Kasper Karmark
- Published
- 2024
- Full Text
- View/download PDF
10. The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines.
- Author
-
Hamm, Sebastian Rask, Loft, Josefine Amalie, Pérez-Alós, Laura, Heftdal, Line Dam, Hansen, Cecilie Bo, Møller, Dina Leth, Pries-Heje, Mia Marie, Hasselbalch, Rasmus Bo, Fogh, Kamille, Hald, Annemette, Ostrowski, Sisse Rye, Frikke-Schmidt, Ruth, Sørensen, Erik, Hilsted, Linda, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, Perch, Michael, Sørensen, Søren Schwartz, and Rasmussen, Allan
- Subjects
BOOSTER vaccines ,HUMORAL immunity ,TRANSPLANTATION of organs, tissues, etc. ,COVID-19 vaccines ,VACCINATION - Abstract
As solid organ transplant (SOT) recipients remain at risk of severe outcomes after SARS-CoV-2 infections, vaccination continues to be an important preventive measure. In SOT recipients previously vaccinated with at least three doses of BNT162b2, we investigated humoral responses to BNT162b2 booster doses. Anti-SARS-CoV-2 receptor binding domain (RBD) immunoglobulin G (IgG) was measured using an in-house ELISA. Linear mixed models were fitted to investigate the change in the geometric mean concentration (GMC) of anti-SARS-CoV-2 RBD IgG after vaccination in participants with intervals of more or less than six months between the last two doses of vaccine. We included 107 SOT recipients vaccinated with a BNT162b2 vaccine. In participants with an interval of more than six months between the last two vaccine doses, we found a 1.34-fold change in GMC per month (95% CI 1.25–1.44), while we found a 1.09-fold change in GMC per month (95% CI 0.89–1.34) in participants with an interval of less than six months between the last two vaccine doses, resulting in a rate ratio of 0.82 (95% CI 0.66 to 1.01, p = 0.063). In conclusion, the administration of identical COVID-19 mRNA vaccine boosters within six months to SOT recipients may result in limited humoral immunogenicity of the last dose. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies.
- Author
-
Heftdal, Line Dam, Hansen, Cecilie Bo, Hamm, Sebastian Rask, Pérez-Alós, Laura, Fogh, Kamille, Pries-Heje, Mia, Hasselbalch, Rasmus Bo, Møller, Dina Leth, Gang, Anne Ortved, Ostrowski, Sisse Rye, Frikke-Schmidt, Ruth, Sørensen, Erik, Hilsted, Linda, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, Sabin, Caroline, Nielsen, Susanne Dam, and Grønbæk, Kirsten
- Subjects
BOOSTER vaccines ,CHRONIC lymphocytic leukemia ,COVID-19 vaccines ,SARS-CoV-2 ,MULTIPLE myeloma ,B cells ,FC receptors - Abstract
To accommodate waning COVID-19 vaccine immunity to emerging SARS-CoV-2 variants, variant-adapted mRNA vaccines have been introduced. Here, we examine serological responses to the BA.1 and BA.4-5 Omicron variant-adapted BNT162b2 COVID-19 vaccines in people with lymphoid malignancies. We included 233 patients with lymphoid malignancies (chronic lymphocytic B-cell leukemia: 73 (31.3%), lymphoma: 89 (38.2%), multiple myeloma/amyloidosis: 71 (30.5%)), who received an Omicron-adapted mRNA-based COVID-19 vaccine. IgG and neutralizing antibodies specific for the receptor-binding domain (RBD) of SARS-CoV-2 were measured using ELISA-based methods. Differences in antibody concentrations and neutralizing capacity and associations with risk factors were assessed using mixed-effects models. Over the period of vaccination with an Omicron-adapted COVID-19 vaccine, the predicted mean concentration of anti-RBD IgG increased by 0.09 log10 AU/mL/month (95% CI: 0.07; 0.11) in patients with lymphoid malignancies across diagnoses. The predicted mean neutralizing capacity increased by 0.9 percent points/month (95% CI: 0.2; 1.6). We found no associations between the increase in antibody concentration or neutralizing capacity and the variant included in the adapted vaccine. In conclusion, a discrete increase in antibody concentrations and neutralizing capacity was found over the course of Omicron-adapted vaccination in patients with lymphoid malignancies regardless of the adapted vaccine variant, indicating a beneficial effect of Omicron-adapted booster vaccination in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Clinical implementation of partial oral treatment in infective endocarditis: the Danish POETry study.
- Author
-
Pries-Heje, Mia Marie, Hjulmand, Julie Glud, Lenz, Ingrid Try, Hasselbalch, Rasmus Bo, Povlsen, Jonas Agerlund, Ihlemann, Nikolaj, Køber, Nana, Tofterup, Marlene Lyngborg, Østergaard, Lauge, Dalsgaard, Morten, Faurholt-Jepsen, Daniel, Wienberg, Malene, Christiansen, Ulrik, Bruun, Niels Eske, Fosbøl, Emil, Moser, Claus, Iversen, Kasper Karmark, and Bundgaard, Henning
- Subjects
INFECTIVE endocarditis ,ORAL drug administration ,POETRY studies ,ENTEROCOCCUS faecalis ,CARDIAC surgery - Abstract
Background and Aims In the Partial Oral Treatment of Endocarditis (POET) trial, stabilized patients with left-sided infective endocarditis (IE) were randomized to oral step-down antibiotic therapy (PO) or conventional continued intravenous antibiotic treatment (IV), showing non-inferiority after 6 months. In this study, the first guideline-driven clinical implementation of the oral step-down POET regimen was examined. Methods Patients with IE, caused by Staphylococcus aureus , Enterococcus faecalis , Streptococcus spp. or coagulase-negative staphylococci diagnosed between May 2019 and December 2020 were possible candidates for initiation of oral step-down antibiotic therapy, at the discretion of the treating physician. The composite primary outcome in patients finalizing antibiotic treatment consisted of embolic events, unplanned cardiac surgery, relapse of bacteraemia and all-cause mortality within 6 months. Results A total of 562 patients [median age 74 years (IQR, interquartile range, 65–80), 70% males] with IE were possible candidates; PO was given to 240 (43%) patients and IV to 322 (57%) patients. More patients in the IV group had IE caused by S. aureus , or had an intra-cardiac abscess, or a pacemaker and more were surgically treated. The primary outcome occurred in 30 (13%) patients in the PO group and in 59 (18%) patients in the IV group (P =.051); in the PO group, 20 (8%) patients died vs. 46 (14%) patients in the IV group (P =.024). PO-treated patients had a shorter median length of stay [PO 24 days (IQR 17–36) vs. IV 43 days (IQR 32–51), P <.001]. Conclusions After clinical implementation of the POET regimen almost half of the possible candidates with IE received oral step-down antibiotic therapy. Patients in the IV group had more serious risk factors for negative outcomes. At 6-month follow-up, there was a numerically but not statistically significant difference towards a lower incidence of the primary outcome, a lower incidence of all-cause mortality and a reduced length of stay in the PO group. Due to the observational design of the study, the lower mortality may to some extent reflect selection bias and unmeasured confounding. Clinical implementation of PO regimens seemed feasible and safe. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Infective Endocarditis Antibiotic Prophylaxis: Review of the Evidence and Guidelines.
- Author
-
Pries-Heje, Mia M., Bundgaard, Henning, Iversen, Kasper K., Baden, Lindsey R., and Woolley, Ann E.
- Abstract
Purpose of Review: The question of antibiotic prophylaxis and its role in prevention of infective endocarditis (IE) remains controversial, with differing recommendations from international societies. The aim of this review was to compare and contrast current recommendations on antibiotic prophylaxis for IE by the American Heart Association (AHA), the European Society of Cardiology (ESC), and the National Institute for Health and Care Excellence (NICE) and highlight the evidence supporting these recommendations. Recent Findings: International guidelines for administration of antibiotic prophylaxis for prevention of IE are largely unchanged since 2009. Studies on the impact of the more restrictive antibiotic prophylaxis recommendations are conflicting, with several studies suggesting lack of adherence to current guidance from the ESC (2015), NICE (2016), and AHA (2021). Summary: The question of antibiotic prophylaxis in patients with IE remains controversial, with differing recommendations from international societies. Despite the change in guidelines more than 15 years ago, lack of adherence to current guidelines persists. Due to the lack of high-quality evidence and the conflicting results from observational studies along with the lack of randomized clinical trials, the question of whether to recommend antibiotic prophylaxis or not in certain patient populations remains unanswered and remains largely based on expert consensus opinion. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis.
- Author
-
Bock, Magnus, Hasselt, Johan G C Van, Schwartz, Franziska, Wang, Hengzhuang, Høiby, Niels, Fuursted, Kurt, Ihlemann, Nikolaj, Gill, Sabine, Christiansen, Ulrik, Bruun, Niels Eske, Elming, Hanne, Povlsen, Jonas A, Køber, Lars, Høfsten, Dan E, Fosbøl, Emil L, Pries-Heje, Mia M, Christensen, Jens Jørgen, Rosenvinge, Flemming S, Torp-Pedersen, Christian, and Helweg-Larsen, Jannik
- Subjects
INFECTIVE endocarditis ,LINEZOLID ,RIFAMPIN ,ORAL drug administration - Abstract
Background Linezolid in combination with rifampicin has been used in treatment of infective endocarditis especially for patients infected with staphylococci. Objectives Because rifampicin has been reported to reduce the plasma concentration of linezolid, the present study aimed to characterize the population pharmacokinetics of linezolid for the purpose of quantifying an effect of rifampicin cotreatment. In addition, the possibility of compensation by dosage adjustments was evaluated. Patients and methods Pharmacokinetic measurements were performed in 62 patients treated with linezolid for left-sided infective endocarditis in the Partial Oral Endocarditis Treatment (POET) trial. Fifteen patients were cotreated with rifampicin. A total of 437 linezolid plasma concentrations were obtained. The pharmacokinetic data were adequately described by a one-compartment model with first-order absorption and first-order elimination. Results We demonstrated a substantial increase of linezolid clearance by 150% (95% CI: 78%–251%), when combined with rifampicin. The final model was evaluated by goodness-of-fit plots showing an acceptable fit, and a visual predictive check validated the model. Model-based dosing simulations showed that rifampicin cotreatment decreased the PTA of linezolid from 94.3% to 34.9% and from 52.7% to 3.5% for MICs of 2 mg/L and 4 mg/L, respectively. Conclusions A substantial interaction between linezolid and rifampicin was detected in patients with infective endocarditis, and the interaction was stronger than previously reported. Model-based simulations showed that increasing the linezolid dose might compensate without increasing the risk of adverse effects to the same degree. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies.
- Author
-
Heftdal, Line Dam, Hamm, Sebastian Rask, Pérez‐Alós, Laura, Madsen, Johannes Roth, Armenteros, Jose Juan Almagro, Fogh, Kamille, Kronborg, Christoffer Cronwald, Vallentin, Anders Pommer, Hasselbalch, Rasmus Bo, Møller, Dina Leth, Hansen, Cecilie Bo, Pries‐Heje, Mia, Gang, Anne Ortved, Ostrowski, Sisse Rye, Frikke‐Schmidt, Ruth, Sørensen, Erik, Hilsted, Linda, Bundgaard, Henning, Iversen, Kasper, and Garred, Peter
- Subjects
HUMORAL immunity ,SARS-CoV-2 ,CORONAVIRUS diseases ,HEMATOLOGIC malignancies ,COVID-19 ,COVID-19 vaccines - Abstract
Objectives: Initial responses to coronavirus disease 2019 vaccination are impaired in patients with hematological malignancies. We investigated immune responses after three or four doses of BNT162b2 in patients with myeloid and lymphoid malignancies compared to controls, and identified risk factors for humoral and cellular nonresponse 1 year after first vaccination. Methods: In 407 hematological patients (45 myeloid, 362 lymphoid) and 98 matched controls, we measured immunoglobulin G (IgG) and neutralizing antibodies specific for the receptor‐binding domain of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) at baseline, 3 weeks, 2, 6, and 12 months, and interferon‐γ release at 12 months. Results: In patients with lymphoid malignancies, SARS‐CoV‐2 receptor‐binding domain IgG concentration and mean neutralizing capacity was lower than in controls at all time points. A diagnosis of chronic lymphocytic B‐cell leukemia (CLL) or lymphoma was associated with humoral nonresponse at 12 months compared to having multiple myeloma/amyloidosis (p <.001 and p =.013). Compared to controls, patients with lymphoid malignancies had increased risk of cellular nonresponse. A lymphoma diagnosis was associated with lower risk of cellular nonresponse compared to patients with multiple myeloma/amyloidosis, while patients with CLL had comparable response rates to patients with multiple myeloma/amyloidosis (p =.037 and p =.280). Conclusions: In conclusion, long‐term humoral and cellular immune responses to BNT162b2 were impaired in patients with lymphoid malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy.
- Author
-
Bock, Magnus, Theut, Anna Marie, Hasselt, Johan G C van, Wang, Hengzhuang, Fuursted, Kurt, Høiby, Niels, Lerche, Christian Johann, Ihlemann, Nikolaj, Gill, Sabine, Christiansen, Ulrik, Nielsen, Hans Linde, Lemming, Lars, Elming, Hanne, Povlsen, Jonas A, Bruun, Niels Eske, Høfsten, Dan, Fosbøl, Emil L, Køber, Lars, Schultz, Martin, and Pries-Heje, Mia M
- Subjects
ANTIBIOTICS ,QUINOLINE ,ORAL drug administration ,INFECTIVE endocarditis ,DICLOXACILLIN ,LINEZOLID ,RESEARCH funding ,RIFAMPIN ,MICROBIAL sensitivity tests ,AMOXICILLIN ,PHARMACODYNAMICS - Abstract
Background In the POET (Partial Oral Endocarditis Treatment) trial, oral step-down therapy was noninferior to full-length intravenous antibiotic administration. The aim of the present study was to perform pharmacokinetic/pharmacodynamic analyses for oral treatments of infective endocarditis to assess the probabilities of target attainment (PTAs). Methods Plasma concentrations of oral antibiotics were measured at day 1 and 5. Minimal inhibitory concentrations (MICs) were determined for the bacteria causing infective endocarditis (streptococci, staphylococci, or enterococci). Pharmacokinetic/pharmacodynamic targets were predefined according to literature using time above MIC or the ratio of area under the curve to MIC. Population pharmacokinetic modeling and pharmacokinetic/pharmacodynamic analyses were done for amoxicillin, dicloxacillin, linezolid, moxifloxacin, and rifampicin, and PTAs were calculated. Results A total of 236 patients participated in this POET substudy. For amoxicillin and linezolid, the PTAs were 88%–100%. For moxifloxacin and rifampicin, the PTAs were 71%–100%. Using a clinical breakpoint for staphylococci, the PTAs for dicloxacillin were 9%–17%. Seventy-four patients at day 1 and 65 patients at day 5 had available pharmacokinetic and MIC data for 2 oral antibiotics. Of those, 13 patients at day 1 and 14 patients at day 5 did only reach the target for 1 antibiotic. One patient did not reach target for any of the 2 antibiotics. Conclusions For the individual orally administered antibiotic, the majority reached the target level. Patients with sub-target levels were compensated by the administration of 2 different antibiotics. The findings support the efficacy of oral step-down antibiotic treatment in patients with infective endocarditis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study.
- Author
-
Kvist-Hansen, Amanda, Pérez-Alós, Laura, Al-Sofi, Rownaq Fares, Heftdal, Line Dam, Hamm, Sebastian Rask, Møller, Dina Leth, Pries-Heje, Mia Marie, Fogh, Kamille, Hansen, Cecilie Bo, Hasselbalch, Rasmus Bo, Madsen, Johannes Roth, Armenteros, Jose Juan Almagro, Frikke-Schmidt, Ruth, Hilsted, Linda, Sørensen, Erik, Ostrowski, Sisse Rye, Bundgaard, Henning, Nielsen, Susanne Dam, Iversen, Kasper, and Zachariae, Claus
- Subjects
COVID-19 vaccines ,CELLULAR immunity ,HEPATITIS B vaccines ,PSORIASIS ,METHOTREXATE ,BIOLOGICALS - Abstract
Background mRNA-based COVID-19 vaccines have short- and long-term efficacy in healthy individuals, but their efficacy in patients with psoriasis receiving immunomodulatory therapy is less studied. Objectives To investigate long-term immunity after COVID-19 vaccination in patients with psoriasis receiving immunomodulatory therapy. Methods A prospective cohort study including patients (n = 123) with psoriasis receiving methotrexate (MTX) or biologics and controls (n = 226). Only mRNA-based COVID-19 vaccines administered with standard intervals between doses were investigated. Markers of immunity included SARS-CoV-2 spike glycoprotein-specific IgG and IgA, neutralizing capacity, and interferon-γ release from T cells stimulated with peptides of the SARS-CoV-2 spike glycoprotein. Results The proportion of IgG responders was lower 6 months after vaccination in patients receiving anti-tumour necrosis factor (TNF) treatment compared with controls. Anti-TNF treatment was associated with lower IgG levels (β = −0.82, 95% confidence interval −1.38 to −0.25; P = 0.001). The median neutralizing index was lower in the anti-TNF group [50% inhibition (interquartile range [IQR] 37–89)] compared with controls [98% inhibition (IQR 96–99)]; P < 0.001. Cellular responses were numerically lowest in the anti-TNF group. Conclusions Treatment with anti-TNF has an impact on the immunity elicited by mRNA-based COVID-19 vaccination in patients with psoriasis, resulting in a faster waning of humoral and cellular markers of immunity; however, the clinical implications are unknown. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection.
- Author
-
Rezahosseini, Omid, Hamm, Sebastian Rask, Heftdal, Line Dam, Pérez-Alós, Laura, Møller, Dina Leth, Perch, Michael, Madsen, Johannes Roth, Hald, Annemette, Bo Hansen, Cecilie, Almagro Armenteros, Jose Juan, Pries-Heje, Mia Marie, Bo Hasselbalch, Rasmus, Fogh, Kamille, Frikke-Schmidt, Ruth, Hilsted, Linda Maria, Sørensen, Erik, Ostrowski, Sisse Rye, Harboe, Zitta Barrella, Iversen, Kasper, and Bundgaard, Henning
- Subjects
MEDICAL personnel ,TRANSPLANTATION of organs, tissues, etc. ,COVID-19 vaccines ,SARS-CoV-2 ,LUNG transplantation - Abstract
Introduction: We investigated humoral and T-cell responses within 12 months after first BNT162b2 vaccine in solid organ transplant (SOT) recipients and controls who had received at least three vaccine doses. Furthermore, we compared the immune response in participants with and without previous SARS-CoV-2 infection. Methods: We included adult liver, lung, and kidney transplant recipients, and controls were selected from a parallel cohort of healthcare workers. Results: At 12th-month, the IgG geometric mean concentrations (GMCs) (P<0.001), IgA GMCs (P=0.003), andmedian IFN-g (P<0.001)were lower in SOT recipients than in controls. However, in SOT recipients and controls with previous infection, the neutralizing index was 99%, and the IgG, and IgA responses were comparable. After adjustment, female-sex (aOR: 3.6, P<0.009), kidney (aOR: 7.0, P= 0.008) or lung transplantation (aOR: 7.5, P= 0.014), and use of mycophenolate (aOR: 5.2, P=0.03) were associated with low IgG non response. Age (OR:1.4, P=0.038), time from transplantation to first vaccine (OR: 0.45, P<0.035), and previous SARS-CoV-2 infection (OR: 0.14, P<0.001), were associated with low IgA non response. Diabetes (OR:2.4, P=0.044) was associated with T-cell non response. Conclusion: In conclusion, humoral and T-cell responses were inferior in SOT recipients without previous SARS-CoV-2 infection but comparable to controls in SOT recipients with previous infection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Effect of Influenza Vaccination on Risk of Coronavirus Disease 2019: A Prospective Cohort Study of 46 000 Healthcare Workers.
- Author
-
Kristensen, Jonas Henrik, Hasselbalch, Rasmus Bo, Pries-Heje, Mia, Nielsen, Pernille Brok, Knudsen, Andreas Dehlbæk, Fogh, Kamille, Norsk, Jakob Boesgaard, Eiken, Aleksander, Andersen, Ove, Fischer, Thea Kølsen, Jensen, Claus Antonio Juul, Torp-Pedersen, Christian, Rungby, Jørgen, Ditlev, Sisse Bolm, Hageman, Ida, Møgelvang, Rasmus, Gybel-Brask, Mikkel, Dessau, Ram Benny, Sørensen, Erik, and Harritshøj, Lene
- Abstract
Background The purpose of this study was to assess whether influenza vaccination has an impact on the risk of coronavirus disease 2019 (COVID-19). Methods A cohort of 46 112 healthcare workers were tested for antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and filled in a survey on COVID-19 symptoms, hospitalization, and influenza vaccination. Results The risk ratio of hospitalization due to SARS-CoV-2 for influenza vaccinated compared with unvaccinated participants was 1.00 for the seasonal vaccination in 2019/2020 (confidence interval,.56–1.78, P = 1.00). Likewise, no clinical effect of influenza vaccination on development of antibodies against SARS-CoV-2 was found. Conclusions The present findings indicate that influenza vaccination does not affect the risk of SARS-CoV-2 infection or COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Severity of anaemia and association with all-cause mortality in patients with medically managed left-sided endocarditis.
- Author
-
Pries-Heje, Mia Marie, Hasselbalch, Rasmus Bo, Wiingaard, Christoffer, Fosbøl, Emil Loldrup, Glenthøj, Andreas Birkedal, Ihlemann, Nikolaj, Gill, Sabine Ute Alice, Christiansen, Ulrik, Elming, Hanne, Bruun, Niels Eske, Povlsen, Jonas Agerlund, Helweg-Larsen, Jannik, Schultz, Martin, Østergaard, Lauge, Fursted, Kurt, Christensen, Jens Jørgen, Rosenvinge, Flemming, Køber, Lars, Tønder, Niels, and Moser, Claus
- Subjects
ANTIBIOTICS ,RESEARCH ,ORAL drug administration ,RESEARCH methodology ,ENDOCARDITIS ,EVALUATION research ,INFECTIVE endocarditis ,COMPARATIVE studies ,RANDOMIZED controlled trials ,ANEMIA - Abstract
Objective: To assess the prevalence and severity of anaemia in patients with left-sided infective endocarditis (IE) and association with mortality.Methods: In the Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis trial, 400 patients with IE were randomised to conventional or partial oral antibiotic treatment after stabilisation of infection, showing non-inferiority. Haemoglobin (Hgb) levels were measured at randomisation. Primary outcomes were all-cause mortality after 6 months and 3 years. Patients who underwent valve surgery were excluded due to competing reasons for anaemia.Results: Out of 400 patients with IE, 248 (mean age 70.6 years (SD 11.1), 62 women (25.0%)) were medically managed; 37 (14.9%) patients had no anaemia, 139 (56.1%) had mild anaemia (Hgb <8.1 mmol/L in men and Hgb <7.5 mmol/L in women and Hgb ≥6.2 mmol/L) and 72 (29.0%) had moderate to severe anaemia (Hgb <6.2 mmol/L). Mortality rates in patients with no anaemia, mild anaemia and moderate to severe anaemia were 2.7%, 3.6% and 15.3% at 6-month follow-up and 13.5%, 20.1% and 34.7% at 3-year follow-up, respectively. Moderate to severe anaemia was associated with higher mortality after 6 months (HR 4.81, 95% CI 1.78 to 13.0, p=0.002) and after 3 years (HR 2.14, 95% CI 1.27 to 3.60, p=0.004) and remained significant after multivariable adjustment.Conclusion: Moderate to severe anaemia was present in 29% of patients with medically treated IE after stabilisation of infection and was independently associated with higher mortality within the following 3 years. Further investigations are warranted to determine whether intensified treatment of anaemia in patients with IE might improve outcome. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
21. Humoral response to two doses of BNT162b2 vaccination in people with HIV.
- Author
-
Heftdal, Line Dam, Knudsen, Andreas Dehlbæk, Hamm, Sebastian Rask, Hansen, Cecilie Bo, Møller, Dina Leth, Pries‐Heje, Mia, Fogh, Kamille, Hasselbalch, Rasmus Bo, Jarlhelt, Ida, Pérez‐Alós, Laura, Hilsted, Linda Maria, Ostrowski, Sisse Rye, Gerstoft, Jan, Grønbæk, Kirsten, Bundgaard, Henning, Iversen, Kasper, Garred, Peter, and Nielsen, Susanne Dam
- Subjects
AIDS vaccines ,HUMORAL immunity ,COVID-19 vaccines ,HIV-positive persons ,ANTIBODY formation - Abstract
Background: People with HIV (PWH) are at increased risk of severe COVID‐19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2. Methods: In 269 PWH and 538 age‐matched controls, we measured IgG and neutralizing antibodies specific for the receptor‐binding domain of SARS‐CoV‐2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2. Results: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%–97.0%], age‐ and sex‐adjusted p = 0.027) of controls. Conclusions: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
- Author
-
Hamm, Sebastian Rask, Møller, Dina Leth, Pérez-Alós, Laura, Hansen, Cecilie Bo, Pries-Heje, Mia Marie, Heftdal, Line Dam, Hasselbalch, Rasmus Bo, Fogh, Kamille, Madsen, Johannes Roth, Almagro Armenteros, Jose Juan, Knudsen, Andreas Dehlbæk, Poulsen, Johan Runge, Frikke-Schmidt, Ruth, Hilsted, Linda Maria, Sørensen, Erik, Ostrowski, Sisse Rye, Harboe, Zitta Barrella, Perch, Michael, Sørensen, Søren Schwartz, and Rasmussen, Allan
- Subjects
COVID-19 vaccines ,SARS-CoV-2 ,TRANSPLANTATION of organs, tissues, etc. ,VACCINE effectiveness ,IMMUNOGLOBULIN G - Abstract
Background: Previous studies have indicated inferior responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination in solid organ transplant (SOT) recipients. We examined the development of anti-receptor-binding domain (RBD) immunoglobulin G (IgG) after two doses of BNT162b2b in SOT recipients 6 months after vaccination and compared to that of immunocompetent controls. Methods: We measured anti-RBD IgG after two doses of BNT162b2 in 200 SOT recipients and 200 matched healthy controls up to 6 months after first vaccination. Anti-RBD IgG concentration and neutralizing capacity of antibodies were measured at first and second doses of BNT162b2 and 2 and 6 months after the first dose. T-cell responses were measured 6 months after the first dose. Results: In SOT recipients, geometric mean concentration (GMC) of anti-RBD IgG increased from first to second dose (1.14 AU/ml, 95% CI 1.08–1.24 to 11.97 AU/ml, 95% CI 7.73–18.77) and from second dose to 2 months (249.29 AU/ml, 95% CI 153.70–385.19). Six months after the first vaccine, anti-RBD IgG declined (55.85 AU/ml, 95% CI 36.95–83.33). At all time points, anti-RBD IgG was lower in SOT recipients than that in controls. Fewer SOT recipients than controls had a cellular response (13.1% vs. 59.4%, p < 0.001). Risk factors associated with humoral non-response included age [relative risk (RR) 1.23 per 10-year increase, 95% CI 1.11–1.35, p < 0.001], being within 1 year from transplantation (RR 1.55, 95% CI 1.30–1.85, p < 0.001), treatment with mycophenolate (RR 1.54, 95% CI 1.09–2.18, p = 0.015), treatment with corticosteroids (RR 1.45, 95% CI 1.10–1.90, p = 0.009), kidney transplantation (RR 1.70, 95% CI 1.25–2.30, p = 0.001), lung transplantation (RR 1.63, 95% CI 1.16–2.29, p = 0.005), and de novo non-skin cancer comorbidity (RR 1.52, 95% CI, 1.26–1.82, p < 0.001). Conclusion: Immune responses to BNT162b2 are inferior in SOT recipients compared to healthy controls, and studies aiming to determine the clinical impact of inferior vaccine responses are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Potential Advances of Adjunctive Hyperbaric Oxygen Therapy in Infective Endocarditis.
- Author
-
Lerche, Christian Johann, Schwartz, Franziska, Pries-Heje, Mia Marie, Fosbøl, Emil Loldrup, Iversen, Kasper, Jensen, Peter Østrup, Høiby, Niels, Hyldegaard, Ole, Bundgaard, Henning, and Moser, Claus
- Subjects
HYPERBARIC oxygenation ,INFECTIVE endocarditis ,AGE groups ,HOSPITAL mortality ,BACTERIAL diseases - Abstract
Patients with infective endocarditis (IE) form a heterogeneous group by age, co-morbidities and severity ranging from stable patients to patients with life-threatening complications with need for intensive care. A large proportion need surgical intervention. In-hospital mortality is 15-20%. The concept of using hyperbaric oxygen therapy (HBOT) in other severe bacterial infections has been used for many decades supported by various preclinical and clinical studies. However, the availability and capacity of HBOT may be limited for clinical practice and we still lack well-designed studies documenting clinical efficacy. In the present review we highlight the potential beneficial aspects of adjunctive HBOT in patients with IE. Based on the pathogenesis and pathophysiological conditions of IE, we here summarize some of the important mechanisms and effects by HBOT in relation to infection and inflammation in general. In details, we elaborate on the aspects and impact of HBOT in relation to the host response, tissue hypoxia, biofilm, antibiotics and pathogens. Two preclinical (animal) studies have shown beneficial effect of HBOT in IE, but so far, no clinical study has evaluated the feasibility of HBOT in IE. New therapeutic options in IE are much needed and adjunctive HBOT might be a therapeutic option in certain IE patients to decrease morbidity and mortality and improve the long-term outcome of this severe disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Antibody‐dependent neutralizing capacity of the SARS‐CoV‐2 vaccine BNT162b2 with and without previous COVID‐19 priming.
- Author
-
Hansen, Cecilie Bo, Jarlhelt, Ida, Hasselbalch, Rasmus Bo, Hamm, Sebastian Rask, Fogh, Kamille, Pries‐Heje, Mia Marie, Møller, Dina Leth, Heftdal, Line Dam, Pérez‐Alós, Laura, Sørensen, Erik, Larsen, Margit Anita Hørup, Skjoedt, Mikkel‐Ole, Ostrowski, Sisse Rye, Frikke‐Schmidt, Ruth, Bayarri‐Olmos, Rafael, Hilsted, Linda Maria, Bundgaard, Henning, Nielsen, Susanne Dam, Iversen, Kasper Karmark, and Garred, Peter
- Subjects
COVID-19 ,SARS-CoV-2 ,COVID-19 vaccines ,MEDICAL personnel - Abstract
Keywords: antibody neutralization; antibody response; BNT162b2; COVID-19; IgA; IgG; IgM; immunoassays; nucleocapsid protein; RBD; SARS-CoV-2; serology; vaccine EN antibody neutralization antibody response BNT162b2 COVID-19 IgA IgG IgM immunoassays nucleocapsid protein RBD SARS-CoV-2 serology vaccine 1272 1274 3 11/19/21 20211201 NES 211201 Dear Editor, We report data on the antibody response against the SARS-CoV-2 receptor-binding domain (RBD) in healthcare professionals from two hospitals in Copenhagen at baseline and 3 weeks post the first injection with the BNT162b2 mRNA COVID-19 vaccine. Shown are neutralizing antibodies according to age groups (e), anti-RBD IgG antibodies according to age groups (f), neutralizing antibodies according to sex (g) and anti-RBD IgG antibodies according to sex (h). Box plots display the median values with the interquartile range (lower and upper hinge) and the 2.5%-97.5% (lower and upper whiskers): neutralizing antibodies (a), anti-receptor-binding domain (anti-RBD) IgG antibodies (b), anti-RBD IgM antibodies (c) and anti-RBD IgA antibodies (d). [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
25. Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial.
- Author
-
Pries-Heje, Mia M., Iversen, Kasper, and Bundgaard, Henning
- Subjects
- *
RESEARCH , *INTRAVENOUS therapy , *ORAL drug administration , *RESEARCH methodology , *EVALUATION research , *INFECTIVE endocarditis , *TREATMENT effectiveness , *COMPARATIVE studies , *ANTIBIOTICS , *LONGITUDINAL method - Abstract
The article informs that Partial Oral Treatment of Endocarditis (POET) tria 2 stepdown therapy with oral antibiotics after clinical stabilization of patients with endocarditis on the left side of the heart was shown to be noninferior to continued intravenous antibiotic therapy. Topics include Patients in stable condition who had endocarditis on the left side of the heart caused by streptococci; and patients in the group that received intravenous treatment remained hospitalized.
- Published
- 2022
- Full Text
- View/download PDF
26. The Risk Management of COVID-19: Lessons from Financial Economics and Financial Risk Management.
- Author
-
Chance, Don M.
- Subjects
FINANCIAL risk management ,FINANCIAL economics ,RISK managers ,FINANCIAL risk ,DEATH rate - Abstract
The United States had one of the worst outcomes in the management of COVID-19 risk, with a death rate in the 94th percentile of all countries. Setting aside the obvious politicized nature of COVID-19 public health recommendations and mandates, we argue that best practices in financial risk management provide parallels that could have served as valuable guidance. We demonstrate here that considerable signals were missed that would have required very little effort and would have been consistent with sound risk management. We also identify examples of misleading information such as that COVID-19 was particularly hard on the elderly. The data actually show that it had a much greater marginal impact on those not elderly. We show here that financial economists and risk managers have a strong knowledge base of how to process vast quantities of data to distinguish signals from noise and have much to teach the public health establishment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis.
- Author
-
Holm-Yildiz, Sonja, Dysgaard, Tina, Krag, Thomas, Pedersen, Britt Stævnsbo, Hamm, Sebastian Rask, Pérez-Alós, Laura, Hansen, Cecilie Bo, Pries-Heje, Mia Marie, Heftdal, Line Dam, Hasselbalch, Rasmus Bo, Fogh, Kamille, Madsen, Johannes Roth, Frikke-Schmidt, Ruth, Hilsted, Linda Maria, Sørensen, Erik, Ostrowski, Sisse Rye, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, and Nielsen, Susanne Dam
- Subjects
- *
COVID-19 pandemic , *HUMORAL immunity , *MYASTHENIA gravis , *COVID-19 vaccines , *VACCINE effectiveness - Abstract
We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379). • Patients with myasthenia gravis had a humoral response to the COVID-19 vaccine. • Patients on immunosuppressants showed a delayed response to the COVID-19 vaccine. • Long-term humoral vaccine response seemed unaffected by immunosuppressant therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.